Natesto, formerly CompleoTRT, is self-administered via a nasal applicator thereby reducing the risk of secondary exposure to testosterone of women or children. Clinical Research of South Florida (CRSA)
The NDA was based on positive efficacy results from a Phase III clinical trial, in addition to a series of other clinical trials assessing pharmacokinetics, safety and abuse
Currently, Cialis is available worldwide by ‘prescription only’ for the treatment of men with erectile dysfunction (ED). As part of the deal, Sanofi is acquiring the exclusive rights
The company targets end-stage renal disease (ESRD) and chronic kidney disease (CKD) with new products and services to treat iron replacement, secondary hyperparathyroidism and hemodialysis. Triferic is indicated
A portion of the CRADA research program is being sponsored by Intensity Therapeutics. CRADA will explore the processes by which the company’s products activate immune responses against cancer
The company’s ANDA product is a generic version of AstraZeneca and Bristol-Myers Squibb’s Onglyza, which is indicated as an adjunct to diet and exercise to improve glycemic control
The company secured exclusive global OTC rights to NEXIUM from British firm AstraZeneca in August 2012. Nexium 24HR (esomeprazole 20mg) was approved by the US Food and Drug
The products covered under the purchase include Restylane, Perlane and Emervel, which are used to fill wrinkles and increase the fullness of lips. The purchase also covers Dysport
Earlier in 2014, a Final Appraisal Determination (FAD) was issued, which concluded Lemtrada is a cost-effective use of NHS resources for MS treatment, and formed the basis of
MGD010 incorporates MacroGenics’ proprietary platform for Dual-Affinity Re-Targeting (DART) to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins. Currently, MGD010 is in pre-clinical development for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.